Sugi Predict
/ Targets
/ IL1R1
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to IL1R1 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| An Efficacy and Safety Study of GNR-086 (Canakinumab Biosimilar) and Ilaris® in Patients With Adult-onset Still's Disease |
PHASE3 | COMPLETED |
| Preoperative Glucocorticoid Use in Major Hepatectomy |
PHASE2/PHASE3 | COMPLETED |
| Late Phase Administration Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation |
PHASE1/PHASE2 | WITHDRAWN |
| Early Phase Administration of Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation |
PHASE1/PHASE2 | WITHDRAWN |
| Anti-inflammatory Therapy With Anakinra in Newly Diagnosed Type 1 Diabetes |
PHASE1/PHASE2 | COMPLETED |
| The Benefit of Bermekimab in Patients With Systemic Sclerosis |
PHASE2 | COMPLETED |
| Colchicine and Inflammation in Hemodialysis Patients |
PHASE2 | UNKNOWN |
| IL1-TRAP, Rilonacept, in Systemic Sclerosis |
PHASE1/PHASE2 | COMPLETED |
| Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction |
PHASE2 | COMPLETED |
| Interleukin-1 Receptor Antagonist and Insulin Sensitivity |
PHASE2 | UNKNOWN |
| Anakinra in Hidradenitis Suppurativa |
PHASE2 | COMPLETED |
| suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE) |
PHASE2 | COMPLETED |
| Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA) |
PHASE2 | COMPLETED |
| Anakinra as a Rescue Treatment for Allergic Inflammation |
PHASE1/PHASE2 | WITHDRAWN |
| A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy |
PHASE1 | COMPLETED |
| IL-1 Receptor Inhibitor for Granulomatous Complications in Patients With Chronic Granulomatous Disease |
EARLY_PHASE1 | COMPLETED |
| Assessment of Salivary GM-CSF, MIP, and IL-1β Levels in Subjects With Varying Periodontal Conditions |
nan | RECRUITING |
| The Value of Interleukin-1β and Interleukin-33 Genetic Expression in the Pathogenesis and Differentiation of Primary ITP and SLE-Related Thrombocytopenia |
nan | NOT_YET_RECRUITING |
| The Role of Toll-like Receptor-4 in Periodontitis Patients With End-stage Renal Disease in a Sample of Egyptian Population |
nan | RECRUITING |
| Clinical Phenotypes in Pericarditis: IL-1RA Antibodies and suPAR Levels |
nan | RECRUITING |
| Periduroscopy: Correlation Between the Outcome of Procedure and Histological-biochemical, Neuroinflammation and Genetic Factors. |
nan | UNKNOWN |
| Interleukin-34 in Stage I and II Periodontitis |
nan | COMPLETED |
| Probiotics and Systemic Inflammation in Patients With Metabolic Syndrome and High Cardiovascular Risk |
nan | WITHDRAWN |
| The Mechanisms and Significances of Synergistic Effects of Mycophenolic Acid and LPS on IL-1β Secretion by Mononuclear |
nan | UNKNOWN |
| The Role Of Neutrophil Proteases As Global Regulators Of Il-1 Family Cytokine Activity In Skin Disorders |
nan | UNKNOWN |
| Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry Bad Cholesterol in the Blood |
nan | COMPLETED |
| Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases) |
nan | RECRUITING |
| Acupuncture for Reduction of Inflammation |
nan | COMPLETED |
| Effects of Spinal Manipulative Treatment on Inflammatory Markers in Low Back Pain Patients |
nan | COMPLETED |
| Effects of IL-1β and Its Receptor Antagonists in the Treatment of Severe Infection and Inflammatory Storm in Children |
nan | WITHDRAWN |
Related proteins — ESM-2 sequence neighbours (a IL1R1 binder may also engage these)